A novel immunofluorescent test system for SARS-CoV-2 detection in infected cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
26
02
2024
accepted:
14
05
2024
medline:
31
5
2024
pubmed:
31
5
2024
entrez:
31
5
2024
Statut:
epublish
Résumé
Highly variable pandemic coronavirus SARS-CoV-2, which causes the hazardous COVID-19 infection, has been persistent in the human population since late 2019. A prompt assessment of individual and herd immunity against the infection can be accomplished by using rapid tests to determine antiviral antibody levels. The microneutralization assay (MN) is one of the most widely used diagnostic methods that has been proposed to assess the qualitative and quantitative characteristics of virus-specific humoral immunity in COVID-19 convalescents or vaccine recipients. However, some aspects of the assay, such as sensitivity and time cost, need improvement. Here, we developed an express test, which may be potentially used in clinical practice for the assessment of serum-caused SARS-CoV-2 inhibition in infected cell cultures. It implies the detection and counting of coronaviral fluorescent-forming units (FFU) and includes two sequentially used developing components: biotinylated mouse monoclonal antibodies against the recombinant N protein of SARS-CoV-2 (B.1) and the recombinant EGFP-streptavidin fusion protein. Due to the universal specificity of the antibodies, our analytical tool is suitable for the detection of various strains of SARS-CoV-2 when determining both the infectious titer of viruses and the titer of serum virus-neutralizing antibodies. The developed two-component test system is characterized by high sensitivity, a reduced number of analytic stages and low assay cost, as well as by flexibility, since it may be modified for detection of other pathogens using the appropriate antibodies.
Identifiants
pubmed: 38820303
doi: 10.1371/journal.pone.0304534
pii: PONE-D-24-07586
doi:
Substances chimiques
Antibodies, Viral
0
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0304534Informations de copyright
Copyright: © 2024 Rak et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Clin Microbiol Rev. 2021 May 12;34(3):
pubmed: 33980687
Biochem Biophys Res Commun. 2021 Jan 29;538:187-191
pubmed: 33187644
Mil Med Res. 2021 Aug 31;8(1):47
pubmed: 34465396
Front Microbiol. 2014 Apr 17;5:172
pubmed: 24860555
Eur J Intern Med. 2021 Jul;89:97-103
pubmed: 34090748
Ann N Y Acad Sci. 1964 Dec 28;121:404-27
pubmed: 14240539
Viruses. 2023 Jan 13;15(1):
pubmed: 36680269
Cold Spring Harb Perspect Med. 2022 May 27;12(5):
pubmed: 35444005
Sci Adv. 2022 Jan 21;8(3):eabm4034
pubmed: 35044811
Pathogens. 2021 Jan 30;10(2):
pubmed: 33573221
Vaccine. 2015 Sep 22;33(39):5110-7
pubmed: 26296497
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
Viruses. 2021 Jun 10;13(6):
pubmed: 34200602
Viruses. 2021 May 12;13(5):
pubmed: 34065987
Vaccines (Basel). 2023 Mar 03;11(3):
pubmed: 36992173
Sci Adv. 2022 Aug 5;8(31):eabp9770
pubmed: 35921414
Exp Mol Med. 2021 Apr;53(4):537-547
pubmed: 33864026
EClinicalMedicine. 2021 Feb;32:100734
pubmed: 33589882
PLoS One. 2022 Jul 28;17(7):e0272298
pubmed: 35901110
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Elife. 2020 Apr 02;9:
pubmed: 32228860
J Clin Virol. 2022 Feb;147:105064
pubmed: 35033881
Diagnostics (Basel). 2021 May 30;11(6):
pubmed: 34070824
Nat Protoc. 2021 Jun;16(6):3114-3140
pubmed: 33893470
Viruses. 2021 Apr 10;13(4):
pubmed: 33920222